Fidelity files Form 144 to sell VRTX shares

Fidelity Brokerage Services LLC filed a Form 144 reporting a proposed sale of common shares of Vertex Pharmaceuticals.

Rhea-AI Filing Summary

Fidelity Brokerage Services LLC filed a Form 144 reporting a proposed sale of common shares of Vertex Pharmaceuticals. The notice lists multiple grant/purchase dates and share lots tied to ESPP purchases and restricted stock vesting, including a line showing 2,394,365 (units) and an NASDAQ listing reference. The filing enumerates specific lot dates and share counts that the filer may sell under Rule 144.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filed for VRTX mean?

A Form 144 notifies the SEC of an intent to sell restricted or control securities under Rule 144. It lists specific share lots, acquisition dates, and counts so potential market participants can see the proposed resale details before transactions occur.

How many VRTX shares are referenced in this Form 144?

The filing text includes a numeric line showing 2,394,365 (units) alongside other entries. The notice also lists multiple lot-level share counts tied to ESPP purchases and restricted stock vesting on specific dates.

Who is the filer on the VRTX Form 144?

The Form 144 is filed by Fidelity Brokerage Services LLC, which appears as the selling broker/agent for the reported resale of common shares acquired through ESPP purchases and restricted stock vesting.

Do the listed acquisition dates on the form affect sale eligibility?

The form lists acquisition dates (e.g., 05/14/2022, 02/10/2025) and lot counts; Rule 144 resale eligibility depends on holding periods and conditions tied to those acquisition dates, which are shown in the filing for each lot.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 11:28 AM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002062139
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	VERTEX PHARMACEUTICALS INC / MA
SEC File Number	000-19319
Address of Issuer	50 NORTHERN AVENUE BOSTON MASSACHUSETTS 02210
Phone	6173416393
Name of Person for Whose Account the Securities are To Be Sold	McKechnie Duncan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	4910	2394365.00	254034190	02/25/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/14/2022	ESPP Purchase	Issuer			89	05/14/2022	Cash
Common	11/14/2022	ESPP Purchase	Issuer			57	11/14/2022	Cash
Common	05/14/2023	ESPP Purchase	Issuer			59	05/14/2023	Cash
Common	11/14/2023	ESPP Purchase	Issuer			23	11/14/2023	Cash
Common	05/14/2024	ESPP Purchase	Issuer			52	05/14/2024	Cash
Common	11/14/2024	ESPP Purchase	Issuer			18	11/14/2024	Cash
Common	02/10/2025	Restricted Stock Vesting	Issuer			2017	02/10/2025	Compensation
Common	02/17/2025	Restricted Stock Vesting	Issuer			1224	02/17/2025	Compensation
Common	02/24/2025	Restricted Stock Vesting	Issuer			331	02/24/2025	Compensation
Common	02/26/2025	Restricted Stock Vesting	Issuer			994	02/26/2025	Compensation
Common	05/14/2025	ESPP Purchase	Issuer			46	05/14/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/25/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/25/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Duncan J. Mckechnie
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)